These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 2690415)
1. Antibiotic resistance in the tropics. 3. Medical responsibilities of the pharmaceutical industry with respect to use of antibiotics in the tropics. Salter AJ Trans R Soc Trop Med Hyg; 1989; 83(1):45-8. PubMed ID: 2690415 [TBL] [Abstract][Full Text] [Related]
2. [AIDS and social justice: pharmaceutical industry and economics]. López Guzmán J Cuad Bioet; 2008; 19(67):563-74. PubMed ID: 19166259 [TBL] [Abstract][Full Text] [Related]
3. Strategies for the rational use of antimicrobials. Couper MR Clin Infect Dis; 1997 Jan; 24 Suppl 1():S154-6. PubMed ID: 8994798 [TBL] [Abstract][Full Text] [Related]
4. The drugging of the Third World. Silverman M; Lee PR; Lydecker M Int J Health Serv; 1982; 12(4):585-96. PubMed ID: 7141775 [TBL] [Abstract][Full Text] [Related]
5. Essential and non-essential drugs marketed by the 20 largest European pharmaceutical companies in developing countries. Hartog R Soc Sci Med; 1993 Oct; 37(7):897-904. PubMed ID: 8211308 [TBL] [Abstract][Full Text] [Related]
6. New countermeasures considered as drug counterfeiting grows. Schubert C Nat Med; 2008 Jul; 14(7):700. PubMed ID: 18607355 [No Abstract] [Full Text] [Related]
7. When medicine becomes a disease. Arabia; 1986 Mar; 5(55):32-6. PubMed ID: 12340711 [TBL] [Abstract][Full Text] [Related]
12. Commercial drug compendium information: a First World/Third World comparison. Pleil AM; Pathak DS Int J Health Serv; 1988; 18(4):587-602. PubMed ID: 3235245 [TBL] [Abstract][Full Text] [Related]
13. [Resistance problems in developing countries--use and misuse of antiinfective agents]. Gundersen SG Tidsskr Nor Laegeforen; 1992 Sep; 112(21):2741-6. PubMed ID: 1412304 [TBL] [Abstract][Full Text] [Related]
14. Drug promotion and labeling in developing countries: an update. Lee PR; Lurie P; Silverman MM; Lydecker M J Clin Epidemiol; 1991; 44 Suppl 2():49S-55S. PubMed ID: 2045842 [TBL] [Abstract][Full Text] [Related]
15. Antibiotic resistance: a view from the pharmaceutical industry. Bax RP Clin Infect Dis; 1997 Jan; 24 Suppl 1():S151-3. PubMed ID: 8994797 [TBL] [Abstract][Full Text] [Related]
16. Health and economic consequences of counterfeit drugs. Seiter A Clin Pharmacol Ther; 2009 Jun; 85(6):576-8. PubMed ID: 19451909 [TBL] [Abstract][Full Text] [Related]
17. [Problems of drug resistance in developing countries--use and abuse of anti-infective agents]. Gundersen SG Nord Med; 1992; 107(11):283-8. PubMed ID: 1448344 [TBL] [Abstract][Full Text] [Related]
18. Antibiotic cycling and marketing into the 21st century: a perspective from the pharmaceutical industry. Lavin BS Infect Control Hosp Epidemiol; 2000 Jan; 21(1 Suppl):S32-5. PubMed ID: 10654633 [TBL] [Abstract][Full Text] [Related]
19. Learning from our mistakes: using key opportunities to remove the perverse incentives that help drive antibiotic resistance. Edwards SE; Morel CM Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):685-692. PubMed ID: 31847613 [No Abstract] [Full Text] [Related]
20. Cooperation between developing countries and the pharmaceutical industry in the control of parasitic diseases: a proposal for a practical approach. Van Belle N Soc Sci Med; 1984; 19(10):1109-11. PubMed ID: 6523153 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]